The in vitro susceptibilities of 12 strains of Chlamydia pneumoniae to a new quinolone, OPC-17116; ofloxacin; and sparfloxacin were determined. OPC-17116 was slightly less active than sparfloxacin but more active than ofloxacin, with a MIC for 90% of strains tested and a minimal chiamydiacidal concentration for 90% of strains tested of 0.5 gg/ml.
Chiamydia pneumoniae, the newly described chlamydial species, is emerging as a frequent' cause of community-acquired respiratory tract infections, including pneumonia and bronchitis (1, 2) . Quinolones have attracted interest for their use as potential therapy for community-acquired respiratory tract infections because they are active against a wide range of pathogens responsible for these infections, including Mycoplasma pneumoniae and C. pneumoniae (4) (5) (6) (7) (8) (9) . We previously reported that ofloxacin, temafloxacin, and sparfloxacin had significant activities against C. pneumoniae in vitro (4) . At present, only ofloxacin is available clinically; temafloxacin was withdrawn because of serious adverse effects, and sparfloxacin is still under investigation. OPC-17116, a new quinolone agent currently in phase 3 clinical trials, has excellent tissue penetration and appears to be safe and well tolerated (5) . Therefore, we tested the activities of OPC-17116, ofloxacin, and sparfloxacin against 12 strains of C. pneumoniae in vitro.
Ofloxacin (Ortho Pharmaceuticals, Raritan, N.J.), sparfloxacin (Parke-Davis, Ann Arbor, Mich.), and OPC-17116 (Otsuka America Pharmaceuticals, Inc., Rockville, Md.) were supplied as powders and solubilized according to the instructions from the manufacturers. The following 12 strains of C. pneumoniae were tested: TW-183 (Washington Research Foundation, Seattle, Wash.) and 11 clinical strains, T2023 (ATCC VR1356), T2043 (ATCC VR1355), T2219, T2237, T2263, BAL14, BAL15, BAL16, BAL37, BAL48, and W6805.
Susceptibility testing of C. pneumoniae was performed in cell culture by using HEp-2 cells grown in 96-well microtiter plates (4). Each well was inoculated with 0.1 ml of the test strain diluted to yield 103 to i04 inclusion-forming units per ml, centrifuged at 1,700 x g for 1 h, and incubated at 350C for 1 h. Wells were then aspirated and overlaid with 0.2 ml of medium containing 1 ILg of cycloheximide per ml and serial twofold dilutions of the test drug. After being incubated at 35°C for 72 h, cultures were fixed and stained for inclusions with fluorescein-conjugated antibody to the lipopolysaccharide genus antigen (Pathfinder; Kallestad Diagnostics, Chaska, Minn.). The MIC was the lowest antibiotic concentration at which no inclusions were seen. The minimal chlamydiacidal concentration (MCC) was determined by aspirating the antibiotic-containing medium, washing wells twice with phosphatebuffered saline, and adding antibiotic-free medium. Cultures were frozen at -70°C, thawed, passed onto new cells, incubated for 72 h, and then fixed and stained as described above.
The MCC was the lowest antibiotic concentration which resulted in no inclusions after passage. All tests were run in triplicate.
The MICs and MCCs for C. pneumoniae are given in Table  1 . As concentrations of antibiotics increased, there was a clear breakpoint at which the morphology of the inclusions changed, with the inclusions becoming irregular and progressively smaller or frequently and abruptly becoming fine dust-like particles. These abnormal forms were not viable when passed onto antibiotic-free cells. OPC-17116 gave sharp endpoints compared with those of the other drugs.
Sparfloxacin was the' most active compound tested, with a MIC for 90% of strains tested (MIC90) and an MCC90 of 0.25 jig/ml (Table 1 ). OPC-17116 had similar activity, with a MIC90 and an MCC90 of 0.5 ,ug/ml. Ofloxacin was less active, with a MIC90 and an MCC90 of 1.0 ,ug/ml.
Data on the in vitro susceptibility of C. pneumoniae are limited, in part because of the relatively small number of clinical isolates that have been available for testing. There are only two other reports of the activity of OPC-17116 against C. pneumoniae, and in both only one strain, TW-183, was tested (7, 10) . The MICs and MCCs were 0.06 and 0.03 ,ug/ml, respectively, which is lower than the range we found, 0.25 to 0.5 ,ug/ml. Although results of in vitro testing have been largely consistent, we have noted some interstrain variation in susceptibilities among our isolates in previous studies with other compounds (1) . The results of this study found the MICs and MCCs to be fairly tightly clustered, The activity of OPC-17116 against C. pneumoniae was almost 10-fold less than that reported for C. trachomatis (11 
